N-(4-{(1S)-1-[(4-chlorophenyl)(6-chloro-8-methylquinolin-4-yl)methyl]butyl}benzoyl)-β-alanine | 1215768-07-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-(4-{(1S)-1-[(4-chlorophenyl)(6-chloro-8-methylquinolin-4-yl)methyl]butyl}benzoyl)-β-alanine
• 英文别名: 3-[[4-[(1R,2S)-1-(6-chloro-8-methylquinolin-4-yl)-1-(4-chlorophenyl)pentan-2-yl]benzoyl]amino]propanoic acid
• CAS: 1215768-07-2
• 化学式: C₃₁H₃₀Cl₂N₂O₃
• 分子量: 549.497
• InChiKey: WFLARZCZSIHVNN-IRPSRAIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095256A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式（I）表示的化合物：以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
• GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Lin Songnian

  公开号：US20110172256A1

  公开（公告）日：2011-07-14

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  抑制胰高血糖素受体的化合物被披露。这些化合物对于治疗2型糖尿病及相关疾病非常有用。此外，还包括药物组成和治疗方法。
• Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11077092B2

  公开（公告）日：2021-08-03

  Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.

  本研究公开了胰高血糖素受体拮抗剂与胆固醇吸收抑制剂联合用于治疗糖尿病及相关疾病的方法。
• METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2928497B1

  公开（公告）日：2020-03-25
• ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3082786A1

  公开（公告）日：2016-10-26